Skip to content

Description and Comparison of Biological Vulnerability in Small Vulnerable Newborns Versus Healthy Community Controls in Urban Burkina Faso

Description and Comparison of Biological Vulnerability in Small Vulnerable Newborns Versus Healthy Community Controls in Urban Burkina Faso (DenBalo): Gut Microbiota, Immune System, and Breastmilk Assembly and Development in the First Days and Weeks of Life

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05730569
Acronym
DenBalo
Enrollment
140
Registered
2023-02-16
Start date
2023-01-09
Completion date
2024-07-31
Last updated
2024-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Birth Weight, Preterm Birth, Small for Gestational Age at Delivery

Keywords

Preterm Birth, Low Birth Weight, Small for Gestational Age, Small Vulnerable Newborn

Brief summary

The aim of the DenBalo study is to apply integrated multi-omics methods to examine the biological mechanisms underlying this vulnerability in Small Vulnerable Newborns (SVNs) in LMICs, with the ultimate goal of identifying targeted interventions to reduce morbidity and mortality in this high-risk population. The evidence generated from this project will ultimately help promote healthy pregnancies and the birth of healthy babies. To achieve this goal, three research objectives are proposed: 1. To describe and compare gut microbiota, immune system and breastmilk components in SVNs versus healthy community controls in urban Burkina Faso. 2. To describe and compare the development of the gut microbiota, the immune system and breastmilk components during the first six months of life in SVNs versus healthy community controls in urban Burkina Faso. 3. To investigate the relationship between the composition of the gut microbiota, the immune system and breastmilk components during the first six months of life in SVNs versus healthy community controls in urban Burkina Faso.

Detailed description

The first days and weeks of life are characterized by a truly impressive cascade of biological processes that drive neonatal growth and development-all of which are crucial to preparing the newborn for life outside the womb. First, vaginal delivery exposes neonates to an important natural microbial inoculum from the vaginal microbiota in labor and from the maternal intestinal microbiota at birth. Together, these early colonization events lay the foundation for gut microbiota assembly, inform the arrival of subsequent species through microbial interactions, and dictate infant microbiota maturation. A recent study has shown that a handful of bacteria begin colonizing the infant gut within the first days of life, that gut microbes accumulate gradually over time, and that pioneer strains are retained after a month of life. Whether the gut microbial assembly, maturation, and functional potential differs between SVNs versus healthy, community controls, or is coupled to growth and development, remains unresolved. Secondly, the first days and weeks of life represent a time of heightened vulnerability to infectious disease. Neonatal infections account for a tragic 40% of mortality in children under five years of age. This critical time period is increasingly seen as a key determinant in health over the entire lifespan. A recent study using a high-dimensional, unbiased approach to characterize neonatal immune system development reported a dramatic, purposeful trajectory in the first week of life. While much remains to be explored, what is known is that early microbial colonization is vital to optimal host immune development and protection from disease and that, after birth, the most important determinant of infant gut colonization is breastfeeding. The impacts of preterm birth, low birth weight, or small for gestational age on immune development and function remain enigmatic and the mediating effect of the gut microbiome unknown. Thirdly, neonatal nutrition plays a vital role in the two aforementioned processes-because breastfeeding both initiates tropic priming of the newborn gut and transfers numerous immunological factors to the baby. However, few studies have explored the synergy between neonatal microbiome and immunome development, and even fewer through the lens of newborn nutrition. Moreover, virtually zero studies include an integrated characterization of these processes in the SVN. Evidence suggests that, compared to mothers of full-term neonates, the colostrum from mothers of preterm newborns has higher protein and fat content, free amino acids, sodium, and bioactive milk components including HMOs, cytokines, and lactoferrin. But because few studies have evaluated the association between early milk composition and infant growth and development, it is unclear which components are most imperative for a healthy gut microbiota and a robust immune system, particularly in the SVN. Major advances in systems biology approaches allowing for unbiased, integrated analyses of high-dimensional -omic databases have provided the critical bioinformatic toolkit required to address these questions. Indeed, the ground has never been more fertile for a step-change in commitment to high-impact research on neonatal microbiome and immunome development and the synergy with newborn nutrition.

Interventions

None listed

Sponsors

Institut de Recherche en Sciences de la Santé (IRSS)
CollaboratorUNKNOWN
Université NAZI BONI
CollaboratorOTHER
Hasselt University
CollaboratorOTHER
University of Virginia
CollaboratorOTHER
University Hospital, Ghent
CollaboratorOTHER
Cedars-Sinai Medical Center
CollaboratorOTHER
Sapient Bioanalytics
CollaboratorUNKNOWN
Stanford University
CollaboratorOTHER
Centre Muraz
CollaboratorOTHER
University of Manitoba
CollaboratorOTHER
Manitoba Interdisciplinary Lactation Center (MILC)
CollaboratorUNKNOWN
Agence de Formation, de Recherche & d'Expertise en Santé pour l'Afrique (AFRICSanté)
CollaboratorUNKNOWN
University Ghent
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Fundal height between 24 and 27 cm * Woman living in the health zone of Accart-Ville, Colma 1 or Farakan * Woman not planning to give birth or move outside the study area in the first 6 months of the infant's life * Gestational age between 24 weeks 0 completed day and 29 weeks 6 days (ultrasound) * Monofetal pregnancy without visible malformation * Woman agreeing to give her informed consent to participate in the study * Delivery of a live birth * Vaginal birth * Absence of severe infectious pathology, severe pneumopathy or respiratory distress in the neonate * Neonates who did not receive corticosteroids or antibiotics at birth For Small Vulnerable Newborns (SVNs): * Low birth weight: \<2500g; and/or, * Preterm: born between the 34th and 37th week of pregnancy; and/or, * Small for Gestational Age: \<10 percentile of INTERGROWTH-21st birthweight standards. For healthy community controls: * Neonate born after the 37th week of pregnancy; and, * Birth weight \>2500g; and, * ≥10 percentile of INTERGROWTH-21st birthweight standards; and, * Possible match with a SVN neonate already recruited into the study.

Exclusion criteria

* Fundal height \<24 cm or \>27 cm * Woman living outside the sanitary zone of the Accart-Ville, Colma 1 or Farakan * Woman planning to give birth outside the study area or to move from it within the first 6 months of the infants's life * Gestational age \<24 weeks or ≥30 weeks (ultrasound) * Multi-fetal pregnancy * Malformation visible on ultrasound * Cesarean delivery * Neonate with severe infectious disease, severe pneumopathy or respiratory distress * Neonate who received corticosteroids or antibiotics just after birth

Design outcomes

Primary

MeasureTime frameDescription
Differential abundances of bacterial genera in the infant gut microbiotato be assessed at on days 3, 7, 14, 30, 60, 180 of lifeShotgun metagenomic sequencing

Secondary

MeasureTime frameDescription
Infant gut microbiota α and β diversityto be assessed at on days 3, 7, 14, 30, 60, 180 of lifeShotgun metagenomic sequencing
Infant plasma immunophenotypingto be assessed at birth and on days 1, 3, 5, 7, 30, 60 of lifeFlow cytometry
Infant plasma chemokine and cytokine analysesto be assessed at birth and on days 1, 3, 5, 7, 30, 60 of lifeElectrochemiluminescence and the MSD V-PLEX Human Biomarker 54-Plex Kit
Maternal breastmilk component* profilingon days 3, 7, 14, 30, 60 of life\*Components include macronutrients, micronutrients, oligosaccharides, growth factors, immunoglobulins, cytokines, metabolites, microbes, and proteins.

Other

MeasureTime frameDescription
Maternal plasma chemokine and cytokine analysesto be assessed at birthElectrochemiluminescence and the MSD V-PLEX Human Biomarker 54-Plex Kit
Black carbon exposure in umbilical cord arterial bloodto be assessed at birthWhite-light generation under femtosecond pulsed illumination
Placental DNA adductiomicsto be assessed at birthHybrid Quadrupole Orbitrap MS (Q-Exactive™) high-resolution mass spectrometry (HRMS)
Relative telomere length (TL) in umbilical cord arterial bloodto be assessed at birthqPCR
Infant untargeted metabolomics on capillary whole bloodto be assessed at birth, on days 1, 3, 5, 7, 14, 30 and 60 of lifeModified Agilent RapidFire 360 sample injector coupled to a high-resolution Agilent 6545B liquid chromatography Quadrupole Time-of-Flight (LC/Q-TOF) next-generation rapid liquid chromatography-mass spectrometry (rLC-MS)
Infant untargeted plasma proteomicsto be assessed at birth, on days 1, 3, 5, 7, 14, 30 and 60 of lifeHarmonized Orbitrap Exploris™ liquid chromatography-mass spectrometry (LC-MS)
Infant multiple mycotoxin profiling on capillary whole bloodto be assessed at birth, on days 7, and 14 of lifeLiquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Maternal untargeted capillary whole blood metabolomicsto be assessed at birthModified Agilent RapidFire 360 sample injector coupled to a high-resolution Agilent 6545B liquid chromatography Quadrupole Time-of-Flight (LC/Q-TOF) next-generation rapid liquid chromatography-mass spectrometry (rLC-MS)
Differential abundance of bacterial populations of pregnant or lactating woman (PLW) fecal microbiotato be assessed within 28-30 weeks of gestation, within 33-34 weeks of gestation, on days 7, 14, 30, 60 and 180 of lifeShotgun metagenomic sequencing
Maternal multiple mycotoxin profiling on capillary whole bloodto be assessed at birthLiquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
PLW shotgun vaginal metagenomicsto be assessed 29-30 weeks of gestation, 33-34 weeks of gestation and at birthShotgun metagenomic sequencing
Breastmilk volume intaketo be assessed on days 1, 3, 4, 13 and 14 of lifeDose-to-mother deuterium oxide dilution
Differential abundances of bacterial genera in the infant gut microbiotato be assessed at birth and on days 1, 2, 4, 5, 6 of lifeShotgun metagenomic sequencing
Infant gut microbiota α and β diversityto be assessed at birth and on days 1, 2, 4, 5, 6 of lifeShotgun metagenomic sequencing
Maternal breastmilk component* profilingto be assessed at birth and on days 1, 3, 5 of lifeShotgun metagenomic sequencing
Vaginal cytokinesto be assessed at 29-30 weeks of gestationMulti-plex assay
Maternal untargeted plasma proteomicsto be assessed at birthHarmonized Orbitrap Exploris™ liquid chromatography-mass spectrometry (LC-MS)
PLW Infant fecal microbiota α and β diversityto be assessed within 28-30 weeks of gestation, within 33-34 weeks of gestation, on days 7, 14, 30, 60 and 180 of lifeShotgun metagenomic sequencing
PLW fecal enteropathogensto be assessed within 28-30 weeks of gestation, within 33-34 weeks of gestation, on days 30 and 180 of lifeTaqMan Array Card (TAC) qPCR to detect 62 infection targets of interest, including viruses, bacteria, protozoa and helminths.
Infant fecal enteropathogensto be assessed within 28-30 weeks of gestation, within 33-34 weeks of gestation, on days 30 and 180 of lifeTaqMan Array Card (TAC) qPCR to detect 62 infection targets of interest, including viruses, bacteria, protozoa and helminths.
Maternal plasma immunophenotypingto be assessed at birthFlow cytometry

Countries

Burkina Faso

Contacts

Primary ContactTrenton Dailey-Chwalibóg, MPH, PhD
Trenton@Dailey-Chwalibog.com+33603233614

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026